IMATINIB MESYLATE | A208429 | CHARTWELL RX SCIENCES LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novartis Pharmaceuticals Corporation et al v. Wockhardt Bio AG et al 2 patentsANDA 208429imatinib mesylate | D. Del. | 2016-01-26 | Terminated 2016-12-20 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$2.88
per ea
Lowest NADAC/Unit
$0.6114
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62135065930IMATINIB MESYLATE 400 MG TAB | $2.88 | EA | Generic | — | 2026-08-19 |
| 62135065890IMATINIB MESYLATE 100 MG TAB | $0.6114 | EA | Generic | — | 2026-08-19 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.